Drug Profile
Brepocitinib - Priovant Therapeutics
Alternative Names: Brepocitinib tosylate - Pfizer; PF 6700841; PF-06700841; PF-06700841-15; PF-841Latest Information Update: 04 Apr 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Pfizer; Priovant Therapeutics
- Class Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Arylsulfonic acids; Bridged-ring heterocyclic compounds; Cyclopropanes; Fluorinated hydrocarbons; Ketones; Pyrazoles; Pyrimidines; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dermatomyositis
- Phase II Crohn's disease; Hidradenitis suppurativa; Uveitis
- Discontinued Alopecia; Alopecia areata; Atopic dermatitis; Lupus vulgaris; Plaque psoriasis; Psoriatic arthritis; Systemic lupus erythematosus; Ulcerative colitis; Vitiligo
Most Recent Events
- 02 Apr 2024 Efficacy and adverse events data from the phase II NEPTUNE trial in Uveitis released by Priovant Therapeutics
- 02 Apr 2024 Priovant Therapeutics plans a Phase III trial in Uveitis (PO) in the second half of 2024
- 27 Nov 2023 Discontinued - Phase-II for Systemic lupus erythematosus (In the elderly, Treatment-experienced, In adults) in USA, Argentina, Australia, Bulgaria, Belgium, Canada, China, Colombia, Czech Republic, France, Germany, Greece, Hong Kong, Hungary, Italy, Italy, Japan, South Korea, South Korea, Japan, Mexico, Poland, Portugal, Romania, Serbia, Spain, Taiwan, Ukraine, United Kingdom (PO)